Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Cleveland, Ohio
Treatments:ImmunotherapyHospital:Cleveland Clinic Taussig Cancer Center
Drugs:Journal:Link
Date:Apr 2003

Description:

Patients: This Phase I trial involved 25 patients with metastatic renal cell carcinoma; 18 men and 7 women. The median age was 59. All patients had undergone prior systemic treatments and 19 had undergone prior nephrectomy.

Treatment: The treatment consisted of a novel synthetic type of interferon – consensus interferon (CIFN).

Toxicity: Grade 3-4 toxicities included hypocalcemia, neutropenia, thrombocytopenia, prolonged PT/PTT, respiratory distress/failure, nausea/vomiting, and syncope.

Results: There were no responses and overall median survival was 13.5 months.

Support: The study was supported by a grant from Amgen. Amgen manufactures CIFN.

Correspondence: Thomas E. Hutson, MD





Back